Evidence map›Paper›PMID 39984556›Full record

ArticleScientific reports2025

Author Correction: The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2.

Maihulan Maimaiti, Shinichi Sakamoto, Masahiro Sugiura, Manato Kanesaka, Ayumi Fujimoto, Keisuke Matsusaka, Minhui Xu, Keisuke Ando, Shinpei Saito, Ken Wakai and 8 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Maihulan Maimaiti *Department of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan.
Shinichi Sakamoto *Department of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan. rbatbat1@gmail.com.
Masahiro SugiuraDepartment of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan.
Manato KanesakaDepartment of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan.
Ayumi FujimotoDepartment of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan.
Keisuke MatsusakaDepartment of Pathology, Chiba University Hospital, Chiba, Japan.
Minhui XuBio‑System Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
Keisuke AndoDepartment of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan.
Shinpei SaitoDepartment of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan.
Ken WakaiDepartment of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan.
Yusuke ImamuraDepartment of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan.
Keiichi NakayamaDepartment of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Yoshikatsu KanaiBio‑System Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
Atsushi KanedaDepartment of Molecular Oncology, Chiba University Graduate School of Medicine, Chiba, Japan.
Yuzuru IkeharaDepartment of Tumor Pathology, Chiba University Graduate School of Medicine, Chiba, Japan.
Jun-Ichiro IkedaDepartment of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Naohiko AnzaiDepartment of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.
Tomohiko IchikawaDepartment of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba City, Chiba, 260‑8670, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39984556
PMCPMC11845754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.